Fosun Pharma Reports Strong Shareholder Turnout at 2026 Extraordinary Meetings

An update from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) is now available.

Shanghai Fosun Pharmaceutical has reported the poll results of its first extraordinary general meeting of 2026, along with separate class meetings for A and H shareholders held in Shanghai. The meetings saw participation from both share classes, with more than 42% of the company’s voting share capital represented, reflecting an active level of shareholder engagement.

Certain directors and senior management, including executive directors and a senior manager, abstained from voting on a specific resolution related to shareholdings in a company to be spun off due to their interests in that matter. The company stated that, aside from these disclosed parties, no other shareholders were required to abstain or had indicated opposition, suggesting broad support and limited conflict of interest around the resolutions considered at the meetings.

The most recent analyst rating on (HK:2196) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.

More about Shanghai Fosun Pharmaceutical (Group) Co

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based healthcare group operating in the pharmaceutical industry. The company is listed in Hong Kong and issues both A shares and H shares, serving a broad base of domestic and international investors through its diversified capital market presence.

Average Trading Volume: 3,512,496

Technical Sentiment Signal: Hold

Current Market Cap: HK$75.06B

See more data about 2196 stock on TipRanks’ Stock Analysis page.